LABU vs. CURE

Last updated Apr 1, 2026

Compare and contrast key facts about Direxion Daily S&P Biotech Bull 3x Shares (LABU) and Direxion Daily Healthcare Bull 3x Shares (CURE).

LABU and CURE are both exchange-traded funds (ETFs), meaning they are traded on stock exchanges and can be bought and sold throughout the day. LABU is a passively managed fund by Direxion that tracks the performance of the S&P Biotechnology Select Industry Index (300%). It was launched on May 28, 2015. CURE is a passively managed fund by Direxion that tracks the performance of the Health Care Select Sector Index (300%). It was launched on Jun 15, 2011. Both LABU and CURE are passive ETFs, meaning that they are not actively managed but aim to replicate the performance of the underlying index as closely as possible.

Performance

LABU vs. CURE - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Direxion Daily S&P Biotech Bull 3x Shares (LABU) and Direxion Daily Healthcare Bull 3x Shares (CURE). The values are adjusted to include any dividend payments, if applicable.

LABU vs. CURE - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
LABU Direxion Daily S&P Biotech Bull 3x Shares	4.20%	79.17%	-26.02%	-13.41%	-80.36%	-64.15%	74.66%	75.50%	-57.61%	149.12%
CURE Direxion Daily Healthcare Bull 3x Shares	-17.66%	22.55%	-8.47%	-9.40%	-20.51%	88.30%	5.02%	55.66%	2.82%	69.32%

Returns By Period

In the year-to-date period, LABU achieves a 4.20% return, which is significantly higher than CURE's -17.66% return. Over the past 10 years, LABU has underperformed CURE with an annualized return of -11.81%, while CURE has yielded a comparatively higher 13.32% annualized return.

LABU

• 1D: 22.31%
• 1M: -3.83%
• YTD: 4.20%
• 6M: 78.34%
• 1Y: 175.22%
• 3Y*: 19.86%
• 5Y*: -36.38%
• 10Y*: -11.81%

CURE

• 1D: 5.69%
• 1M: -23.73%
• YTD: -17.66%
• 6M: 10.27%
• 1Y: -12.92%
• 3Y*: -0.17%
• 5Y*: 3.15%
• 10Y*: 13.32%

*Multi-year figures are annualized to reflect compound growth (CAGR)

LABU vs. CURE - Expense Ratio Comparison

LABU has a 1.12% expense ratio, which is higher than CURE's 1.08% expense ratio.

LABU

Direxion Daily S&P Biotech Bull 3x Shares

CURE

Direxion Daily Healthcare Bull 3x Shares

Return for Risk

LABU vs. CURE — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

LABU

LABU Risk / Return Rank: 90
LABU Sharpe Ratio Rank: 92
LABU Sortino Ratio Rank: 90
LABU Omega Ratio Rank: 82
LABU Calmar Ratio Rank: 94
LABU Martin Ratio Rank: 91

CURE

CURE Risk / Return Rank: 9
CURE Sharpe Ratio Rank: 8
CURE Sortino Ratio Rank: 10
CURE Omega Ratio Rank: 10
CURE Calmar Ratio Rank: 8
CURE Martin Ratio Rank: 8

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

LABU vs. CURE - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Direxion Daily S&P Biotech Bull 3x Shares (LABU) and Direxion Daily Healthcare Bull 3x Shares (CURE). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	LABU	CURE	Difference
Sharpe ratio Return per unit of total volatility	2.04	-0.25	+2.28
Sortino ratio Return per unit of downside risk	2.48	0.00	+2.48
Omega ratio Gain probability vs. loss probability	1.31	1.00	+0.31
Calmar ratio Return relative to maximum drawdown	3.74	-0.28	+4.02
Martin ratio Return relative to average drawdown	11.90	-0.50	+12.40
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

LABU vs. CURE - Sharpe Ratio Comparison

The current LABU Sharpe Ratio is 2.04, which is higher than the CURE Sharpe Ratio of -0.25. The chart below compares the historical Sharpe Ratios of LABU and CURE, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	LABU	CURE	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	2.04	-0.25	+2.28
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.38	0.07	-0.45
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	-0.12	0.27	-0.39
Sharpe Ratio (All Time) Calculated using the full available price history	-0.24	0.47	-0.71

Correlation

The correlation between LABU and CURE is 0.59, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.

Dividends

LABU vs. CURE - Dividend Comparison

LABU's dividend yield for the trailing twelve months is around 0.74%, less than CURE's 1.30% yield.

	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017
LABU Direxion Daily S&P Biotech Bull 3x Shares	0.74%	0.84%	0.35%	0.35%	0.00%	0.00%	0.00%	0.28%	0.64%	0.17%
CURE Direxion Daily Healthcare Bull 3x Shares	1.30%	1.12%	1.17%	2.02%	0.38%	0.02%	0.17%	0.40%	0.70%	0.18%

Drawdowns

LABU vs. CURE - Drawdown Comparison

The maximum LABU drawdown since its inception was -99.18%, which is greater than CURE's maximum drawdown of -69.19%. Use the drawdown chart below to compare losses from any high point for LABU and CURE.

Drawdown Indicators

	LABU	CURE	Difference
Max Drawdown Largest peak-to-trough decline	-99.18%	-69.19%	-29.99%
Max Drawdown (1Y) Largest decline over 1 year	-36.66%	-33.92%	-2.74%
Max Drawdown (5Y) Largest decline over 5 years	-97.75%	-52.23%	-45.52%
Max Drawdown (10Y) Largest decline over 10 years	-98.96%	-69.19%	-29.77%
Current Drawdown Current decline from peak	-96.33%	-34.64%	-61.69%
Average Drawdown Average peak-to-trough decline	-81.45%	-17.94%	-63.51%
Ulcer Index Depth and duration of drawdowns from previous peaks	12.01%	20.16%	-8.15%

Volatility

LABU vs. CURE - Volatility Comparison

Direxion Daily S&P Biotech Bull 3x Shares (LABU) has a higher volatility of 33.99% compared to Direxion Daily Healthcare Bull 3x Shares (CURE) at 13.92%. This indicates that LABU's price experiences larger fluctuations and is considered to be riskier than CURE based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	LABU	CURE	Difference
Volatility (1M) Calculated over the trailing 1-month period	33.99%	13.92%	+20.07%
Volatility (6M) Calculated over the trailing 6-month period	56.88%	30.96%	+25.92%
Volatility (1Y) Calculated over the trailing 1-year period	87.36%	52.88%	+34.48%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	95.74%	43.34%	+52.40%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	95.91%	49.47%	+46.44%